Moreover, CD80 (B7-1), B7-2 (CD86)/CTLA-4, and B7-H1 (PD-L1)/PD-1 have been identified as promising targets and their inhibitors have achieved great success in cancer immunotherapy [11]. Here, CD86 is linked to cancer.